Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: A sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)

Jose R. Castillo-Mancilla, Christina L. Aquilante, Michael F. Wempe, Laura M. Smeaton, Cynthia Firnhaber, Alberto M. LaRosa, Nagalingeswaran Kumarasamy, Adriana Andrade, Gautam Baheti, Courtney V. Fletcher, Thomas B. Campbell, David W. Haas, Samantha MaWhinney, Peter L. Anderson

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Objectives: The multinational PEARLS (ACTG A5175) study, conducted mainly in resource-limited settings, identified an increased treatment failure rate among HIV-infected individuals randomized to once-daily unboosted atazanavir, didanosine-EC, and emtricitabine compared with efavirenz-based regimens. We evaluated associations between selected human genetic polymorphisms and atazanavir pharmacokinetics in PEARLS. Methods: Polymorphisms in CYP3A5, ABCB1, SLCO1B1 and NR1I2 were genotyped in PEARLS participants randomized to atazanavir plus didanosine-EC plus emtricitabine in Peru, South Africa and the USA, who also consented to genetic analysis. Non-linear mixed-effects population pharmacokinetic modelling was used to predict atazanavir oral clearance (CL/F) and concentration at 24 h (C24). Atazanavir mono-oxidation metabolites M1 and M2 were quantified from the same single-point plasma sample used to quantify the parent drug. Data were log10 transformed for statistical analysis using unpaired t-tests and one-way ANOVA and are presented as geometric mean (95% CI). Results: Eighty-four HIV-infected participants were genotyped, including 44 Black Africans or African Americans and 28 women. Median agewas 34 years.We identified 56 CYP3A5 expressers and 28 non-expressers. Atazanavir CL/F and C24 did not differ between CYP3A5 expressers and non-expressers: 13.2 (12.1-14.4) versus 12.7 L/h (11.7-13.9), P=0.61, and 75.3 (46.1-123.0) versus 130.9 ng/mL (86.9-197.2), P=0.14, respectively. M1/atazanavir and M2/atazanavir ratios were higher in expressers than in non-expressers: 0.0083 (0.0074-0.0094) versus 0.0063 (0.0053-0.0075), P=0.008, and 0.0065 (0.0057-0.0073) versus 0.0050 (0.0042-0.0061), P=0.02, respectively. Conclusions: Expression of CYP3A5 appears to be associated with increased M1 and M2 atazanavir metabolite formation, without significantly affecting parent compound pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)1609-1618
Number of pages10
JournalJournal of Antimicrobial Chemotherapy
Volume71
Issue number6
DOIs
StatePublished - Jun 13 2016

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology

Fingerprint

Dive into the research topics of 'Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: A sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)'. Together they form a unique fingerprint.

Cite this